Numerous clinical studies have demonstrated similar efficacy of the three CDK4/6 inhibitors in combination with ET, all of which significantly prolong the PFS and ORR of HR+/HER2-breast cancer patients [17]. This evidence concerns the gene HR and breast carcinoma.